These results suggest the binding of β-catenin to CBP or p300 decides CML cell fate, proliferation or differentiation, which is independent of BCR-ABL mutation status. This evidence concerns the gene CREBBP and chronic myelogenous leukemia, BCR-ABL1 positive.